TSCAN THERAPEUTICS INC (TCRX) Stock Fundamental Analysis

NASDAQ:TCRX • US89854M1018

1.03 USD
-0.02 (-1.9%)
At close: Mar 3, 2026
1.035 USD
+0 (+0.49%)
After Hours: 3/3/2026, 4:10:05 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

TCRX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. The financial health of TCRX is average, but there are quite some concerns on its profitability. While showing a medium growth rate, TCRX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • TCRX had negative earnings in the past year.
  • In the past year TCRX has reported a negative cash flow from operations.
  • TCRX had negative earnings in each of the past 5 years.
  • In the past 5 years TCRX always reported negative operating cash flow.
TCRX Yearly Net Income VS EBIT VS OCF VS FCFTCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of TCRX (-54.38%) is comparable to the rest of the industry.
  • TCRX has a Return On Equity of -99.01%. This is comparable to the rest of the industry: TCRX outperforms 45.19% of its industry peers.
Industry RankSector Rank
ROA -54.38%
ROE -99.01%
ROIC N/A
ROA(3y)-33.47%
ROA(5y)-35.77%
ROE(3y)-59.56%
ROE(5y)-72.17%
ROIC(3y)N/A
ROIC(5y)N/A
TCRX Yearly ROA, ROE, ROICTCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for TCRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TCRX Yearly Profit, Operating, Gross MarginsTCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • TCRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TCRX has more shares outstanding
  • The number of shares outstanding for TCRX has been increased compared to 5 years ago.
  • TCRX has a better debt/assets ratio than last year.
TCRX Yearly Shares OutstandingTCRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
TCRX Yearly Total Debt VS Total AssetsTCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -3.38, we must say that TCRX is in the distress zone and has some risk of bankruptcy.
  • TCRX's Altman-Z score of -3.38 is in line compared to the rest of the industry. TCRX outperforms 44.81% of its industry peers.
  • TCRX has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.23, TCRX is not doing good in the industry: 65.38% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z -3.38
ROIC/WACCN/A
WACC9.07%
TCRX Yearly LT Debt VS Equity VS FCFTCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • TCRX has a Current Ratio of 6.44. This indicates that TCRX is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of TCRX (6.44) is better than 65.19% of its industry peers.
  • TCRX has a Quick Ratio of 6.44. This indicates that TCRX is financially healthy and has no problem in meeting its short term obligations.
  • TCRX has a better Quick ratio (6.44) than 65.96% of its industry peers.
Industry RankSector Rank
Current Ratio 6.44
Quick Ratio 6.44
TCRX Yearly Current Assets VS Current LiabilitesTCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for TCRX have decreased by -5.66% in the last year.
  • Looking at the last year, TCRX shows a very negative growth in Revenue. The Revenue has decreased by -10.03% in the last year.
  • TCRX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -34.76% yearly.
EPS 1Y (TTM)-5.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12%
Revenue 1Y (TTM)-10.03%
Revenue growth 3Y-34.76%
Revenue growth 5YN/A
Sales Q2Q%139.37%

3.2 Future

  • Based on estimates for the next years, TCRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.04% on average per year.
  • TCRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 71.81% yearly.
EPS Next Y4.68%
EPS Next 2Y9.82%
EPS Next 3Y7.51%
EPS Next 5Y8.04%
Revenue Next Year207.63%
Revenue Next 2Y50.62%
Revenue Next 3Y56.74%
Revenue Next 5Y71.81%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TCRX Yearly Revenue VS EstimatesTCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
TCRX Yearly EPS VS EstimatesTCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • TCRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TCRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TCRX Price Earnings VS Forward Price EarningsTCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TCRX Per share dataTCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.82%
EPS Next 3Y7.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for TCRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TSCAN THERAPEUTICS INC

NASDAQ:TCRX (3/3/2026, 4:10:05 PM)

After market: 1.035 +0 (+0.49%)

1.03

-0.02 (-1.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-11
Inst Owners73.34%
Inst Owner Change-7.47%
Ins Owners0.26%
Ins Owner Change0%
Market Cap58.45M
Revenue(TTM)8.42M
Net Income(TTM)-142.60M
Analysts80
Price Target7.14 (593.2%)
Short Float %3.83%
Short Ratio3.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.6%
Min EPS beat(2)2.17%
Max EPS beat(2)7.04%
EPS beat(4)3
Avg EPS beat(4)3.16%
Min EPS beat(4)-7.46%
Max EPS beat(4)10.87%
EPS beat(8)6
Avg EPS beat(8)4.64%
EPS beat(12)8
Avg EPS beat(12)7.35%
EPS beat(16)12
Avg EPS beat(16)10.8%
Revenue beat(2)2
Avg Revenue beat(2)69.48%
Min Revenue beat(2)24.31%
Max Revenue beat(2)114.66%
Revenue beat(4)3
Avg Revenue beat(4)44.97%
Min Revenue beat(4)-51.71%
Max Revenue beat(4)114.66%
Revenue beat(8)4
Avg Revenue beat(8)15.52%
Revenue beat(12)5
Avg Revenue beat(12)10.41%
Revenue beat(16)7
Avg Revenue beat(16)9.29%
PT rev (1m)0%
PT rev (3m)10.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)5.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)8.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.94
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-1.12
EYN/A
EPS(NY)-0.91
Fwd EYN/A
FCF(TTM)-2.39
FCFYN/A
OCF(TTM)-2.3
OCFYN/A
SpS0.15
BVpS2.54
TBVpS2.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -54.38%
ROE -99.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.47%
ROA(5y)-35.77%
ROE(3y)-59.56%
ROE(5y)-72.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 179.54%
Cap/Sales 60.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.44
Quick Ratio 6.44
Altman-Z -3.38
F-Score2
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)78.03%
Cap/Depr(5y)175.46%
Cap/Sales(3y)60.67%
Cap/Sales(5y)133.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12%
EPS Next Y4.68%
EPS Next 2Y9.82%
EPS Next 3Y7.51%
EPS Next 5Y8.04%
Revenue 1Y (TTM)-10.03%
Revenue growth 3Y-34.76%
Revenue growth 5YN/A
Sales Q2Q%139.37%
Revenue Next Year207.63%
Revenue Next 2Y50.62%
Revenue Next 3Y56.74%
Revenue Next 5Y71.81%
EBIT growth 1Y-24.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.23%
EBIT Next 3Y-3.95%
EBIT Next 5YN/A
FCF growth 1Y-135.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-143.9%
OCF growth 3YN/A
OCF growth 5YN/A

TSCAN THERAPEUTICS INC / TCRX FAQ

What is the ChartMill fundamental rating of TSCAN THERAPEUTICS INC (TCRX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to TCRX.


What is the valuation status of TSCAN THERAPEUTICS INC (TCRX) stock?

ChartMill assigns a valuation rating of 0 / 10 to TSCAN THERAPEUTICS INC (TCRX). This can be considered as Overvalued.


How profitable is TSCAN THERAPEUTICS INC (TCRX) stock?

TSCAN THERAPEUTICS INC (TCRX) has a profitability rating of 1 / 10.


How financially healthy is TSCAN THERAPEUTICS INC?

The financial health rating of TSCAN THERAPEUTICS INC (TCRX) is 4 / 10.